Last update Dec. 20, 2021

C172H265N43O51

Compatible

Safe substance and/or breastfeeding is the best option.

Glucagon-like peptide 1 analogue that stimulates endogenous insulin secretion. Used to treat obesity and type 2 diabetes in combination with other oral antidiabetics, especially metformin. Administered subcutaneously. The most common side effects are nausea, vomiting and diarrhea. Low risk of hypoglycemia in monotherapy.

Since the last update we have not found published data on its excretion in breast milk.

Its pharmacokinetic data (high molecular weight and high percentage of plasma protein binding) make it very unlikely that significant amounts will pass into breast milk. (Serrano 2014)

Due to its protein nature, it deteriorates in the gastrointestinal tract, not being absorbed (Serrano 2014). This low oral bioavailability would make it difficult for it to pass to the infant’s plasma ingesting breast milk, except in preterm infants and in the immediate neonatal period when there may be increased intestinal permeability.

Diet, exercise, and breastfeeding improve blood sugar levels.


See below the information of this related product:

  • Maternal Diabetes mellitus (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)

Alternatives

  • Acarbose (Safe substance and/or breastfeeding is the best option.)
  • Chlorpropamide (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)
  • Exenatide (Safe substance and/or breastfeeding is the best option.)
  • Glibenclamide (Safe substance and/or breastfeeding is the best option.)
  • Hypocaloric Diet (Safe substance and/or breastfeeding is the best option.)
  • Maternal Sport (Safe substance and/or breastfeeding is the best option.)
  • Metformin Hydrochloride (Safe substance and/or breastfeeding is the best option.)
  • Miglitol (Safe substance and/or breastfeeding is the best option.)
  • Tolbutamide (Safe substance and/or breastfeeding is the best option.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

C172H265N43O51 is Liraglutide in Molecular formula.

Is written in other languages:

Groups

C172H265N43O51 belongs to these groups or families:

Tradenames

Main tradenames from several countries containing C172H265N43O51 in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 0 %
Molecular weight 3.751 daltons
Protein Binding 98 %
VD 0.07 l/Kg
Tmax 8 - 12 hours
T½ 13 hours

References

  1. EMA. Liraglutida. Ficha técnica. 2016 Full text (in our servers)
  2. EMA. Liraglutide. Drug Summary. 2016 Full text (in our servers)
  3. Serrano Aguayo P, García de Quirós Muñoz JM, Bretón Lesmes I, Cózar León MV. Tratamiento de enfermedades endocrinológicas durante la lactancia. [Endocrinologic diseases management during breastfeeding.] Med Clin (Barc). 2015 Jan 20;144(2):73-9. Abstract

Total visits

1,683

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM